- Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
-
Lee DH, Srimuninnimit V, Cheng R, Wang X, Orlando M
- KMID: 2403370
- Cancer Res Treat.
- 2015 Oct;47(4):549-554.
- doi: 10.4143/crt.2014.362
Advances in oncology research have led to identification of tumor-specific biomarkers, some of which are important predictive indicators and ideal targets for novel therapeutics. One such biomarker in non-small cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
-
Yang JC, Ahn MJ, Nakagawa K, Tamura T, Barraclough H, Enatsu S, Cheng R, Orlando M
- KMID: 2148491
- Cancer Res Treat.
- 2015 Jul;47(3):424-435.
- doi: 10.4143/crt.2013.266
PURPOSE: A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous non-small cell lung cancer (NSCLC). The majority of patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
-
Lee DH, Lee JS, Wang J, Hsia TC, Wang X, Kim J, Orlando M
- KMID: 2403379
- Cancer Res Treat.
- 2015 Oct;47(4):616-629.
- doi: 10.4143/crt.2014.051
PURPOSE: This subgroup analysis of a phase II trial was conducted to assess possible ethnicity-based trends in efficacy and safety in East Asian (EA) and non-EA populations with nonsquamous non-small... -
- CITED
-
- Close
- SHARE
-
- Close
- Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
-
Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY
- KMID: 2148483
- Cancer Res Treat.
- 2015 Jul;47(3):343-361.
- doi: 10.4143/crt.2014.308
Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
-
Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carlesi R, Cheng R, Kim J, Orlando M, Kang YK
- KMID: 2394805
- Cancer Res Treat.
- 2017 Oct;49(4):851-868.
- doi: 10.4143/crt.2016.176
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate... -
- CITED
-
- Close
- SHARE
-
- Close
- Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
-
Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K
- KMID: 2454321
- Cancer Res Treat.
- 2016 Apr;48(2):458-464.
- doi: 10.4143/crt.2015.135
PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
-
Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M
- KMID: 2394813
- Cancer Res Treat.
- 2017 Oct;49(4):937-946.
- doi: 10.4143/crt.2016.423
PURPOSE: The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone... -
- CITED
-
- Close
- SHARE
-
- Close
- East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
-
Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH, Lee P, Alexandris E, Puri T, Orlando M
- KMID: 2356220
- Cancer Res Treat.
- 2016 Oct;48(4):1177-1186.
- doi: 10.4143/crt.2015.401
PURPOSE: REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients... -
- CITED
-
- Close
- SHARE
-
- Close
